A kind of immunogenic composition, its preparation method and its use

Abstract

The present invention provides an immunogen composition, which includes the following components: a conjugate of a polypeptide and a carrier and the polypeptide, and also provides a method for preparing the immunogen composition, including the following steps: combining the polypeptide with After the conjugate of the carrier and the polypeptide are mixed according to the mass ratio of 1:5-5:1, the mass ratio is preferably 1:1, adding physiological saline to dilute the mixture of the immunogen composition to 2 times the final concentration, Obtain the diluted mixed solution, then add the described immune adjuvant equal to the volume of the diluted mixed solution and dilute to the final concentration to prepare the immunogen composition; the present invention also provides the monoclonal antibody obtained by using the immunogen composition, Finally draw, use the immunogen composition in the present invention to immunize animals, the serum titer of the immunized animals has been significantly improved, greatly increased the positive rate of hybridoma cells in the monoclonal antibody, and reduced the manpower. and waste of material resources.

Description

technical field [0001] The invention belongs to the field of animal immunity, in particular to the field of preparing monoclonal antibodies. Background technique [0002] Since its establishment in 1975, hybridoma technology has played an extremely important role in the fields of modern medical testing and treatment. This technology is to screen hybridoma cells secreting specific antibodies by fusing mouse myeloma cells and plasma cells in vitro. The cells have both the immortality of myeloma cells and the ability of plasma cells to continuously secrete specific antibodies. The culture is performed in vitro and the antibody is produced. Despite the continuous development of hybridoma preparation technology over the years, the traditional monoclonal antibody preparation process is still cumbersome. The fused hybridoma cells have a large screening throughput, and each 96-well plate should take the supernatant of the cells for ELISA screening, and then perform multiple rounds...

AI Technical Summary

Problems solved by technology

If there are too few positive hybridoma cells in the previous screening process, it will cause the following impacts: ①In order to select more positive hybridomas, it is necessary to increase the number of plating plates and fusion times, resulting in a waste of too much culture consumables and Reagents, especially high-cost reagents such as fetal bovine serum; ②More plate numbers and fusion times and lengthy ELISA screening process lead to more human and material resources consumption; ③Prolong the preparation cycle of monoclonal antibodies; The production of cells is particularly important, but the traditional immunization method uses adjuvant mixed with antigen to immunize mice to promote the activation, recruitment and mutual contact of lymphocytes, so as to enhance the immune effect and increase the antibody titer of the body's immune response Commonly used adjuvants include Freund's adjuvant, RIBI adjuvant, aluminum hydroxide adjuvant, etc. However, in practical applications, it is found that the immunogen used in the traditional immunization method cannot meet the requirements of all antigen immunization and monoclonal antibody. Therefore, it is particularly important to develop a new immunogen to increase the titer of antibodies

Images